Incidence and Mortality of Bullous Pemphigoid in France

Joly, P.; Baricault, Sophie; Sparsa, A.; Bernard, Philippe; Bédane, C.; Duvert‐Lehembre, S.; Courville, Philippe; Bravard, P.; Remond, Brigitte; Doffoël-Hantz, V.; Bénichou, Jacques

doi:10.1038/jid.2012.35

Cited by 302 publications

(407 citation statements)

References 38 publications

(66 reference statements)

Supporting

Mentioning

336

Contrasting

Unclassified

Order By: Relevance

“…Büllöz pemfigoid (BP) farklı Avrupa ülkelerinde milyonda 7-43 arasında değişen insidansı ile en sık izlenen edinilmiş otoimmün büllöz hastalıktır [1][2][3][4] . Yakın tarihli çalışmalarda hastalık insidansındaki artış vurgulanmıştır 3 .…”

Section: Introductionunclassified

Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid

Uysal¹,

Yalçın²,

Öktem³

2017

TURKDERM

View full text Add to dashboard Cite

Background and Design:In the era of biological therapies, omalizumab (OMZ), a monoclonal antibody which inhibits IgE, has been postulated to be effective in the treatment of bullous pemphigoid (BP). We report our clinical experience with the use of OMZ in the treatment of BP. Materials and Methods: Retrospective data analyses of eleven patients were performed. Results: Seven patients receiving OMZ treatment demonstrated clinical improvements. Three patients terminated treatment because of intermittent co-morbidities. None of the patients had any significant adverse events. Conclusion: OMZ may be a promising corticosteroid-sparing treatment option for moderate to severe BP patients. Future randomized controlled trials are indicated to evaluate the efficacy of OMZ in the treatment of BP. Büllöz pemfigoid tedavisinde omalizumab kullanımı üzerine klinik deneyimlerimiz

show abstract

Section: Introductionunclassified

Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid

Uysal¹,

Yalçın²,

Öktem³

2017

TURKDERM

View full text Add to dashboard Cite

show abstract

“…Bullous pemphigoid is by far the most frequent autoimmune blistering disease [86][87][88] (reviewed in [89]). Bullous pemphigoid typically presents with tense blisters, erosions on inflamed or otherwise unaffected skin, crusts, and urticariallike erythema [90].…”

Section: Bullous Pemphigoid-like Variantmentioning

confidence: 99%

Clinical features and diagnosis of epidermolysis bullosa acquisita

Vorobyev

Ludwig

Schmidt

2016

Expert Review of Clinical Immunology

100

View full text Add to dashboard Cite

Introduction: Epidermolysis bullosa acquisita (EBA) is a rare autoimmune blistering disease of skin and mucous membranes. EBA is caused by autoantibodies against type VII collagen, which is a major component of anchoring fibrils, attaching epidermis to dermis. Binding of autoantibodies to type VII collagen leads to skin fragility and, finally, blister formation. The clinical picture of EBA is polymorphic, with several distinct phenotypes being described. Despite recent progress in understanding the pathophysiology of EBA, its diagnosis is still challenging. Areas covered: This review provides an update on the clinical manifestations and diagnostic methods of EBA. We searched PubMed using the terms 'epidermolysis bullosa acquisita' covering articles in English between 1 January 2005 and 31 May 2016. Relevant older publications were retrieved form cited literature. Expert commentary: While the clinical picture is highly variable, diagnosis relies on direct immunofluorescence (IF) microscopy of a perilesional skin biopsy. Linear deposits of IgG, IgA and/or C3 along the dermal-epidermal junction with an u-serrated pattern are diagnostic for EBA alike the detection of serum autoantibodies against type VII collagen. Several test systems for the serological diagnosis of EBA have recently become widely available. In some patients, sophisticated diagnostic approaches only available in specialized centers are required. ARTICLE HISTORY

show abstract

“…It is a rare disease with incidence rates of 4 to 22 cases per million [5][6][7] with a higher incidence in Pacific Rim countries;…”

Section: Epidemiologymentioning

confidence: 99%

“…Some diseases are also associated with BP, such as ocular pemphigoid in association with conjunctival inflammation due to Stevens-Johnson syndrome [7] and lichen planus [17] .…”

Section: Pathogenesismentioning

confidence: 99%

“…Although BP is a potentially fatal disease, the exact mortality figures are unknown. Some authors describe estimates ranging from 11 to 48 percent, while other find only a slight increase in mortality finding increased rates of mortality compared subjects without BP [7,17,27] . In one study, the most common causes of death were heart disease, infection, and neurologic disease [26] .…”

Section: Prognosismentioning

confidence: 99%

See 1 more Smart Citation

Bullous pemphigoid appearing as superficial tissue necrosis after irradiation of the breast: Case history and definitive review of the literature

Trombetta

Erb²,

Kudithipudi

et al. 2015

JST

View full text Add to dashboard Cite

Bullous pemphigoid is an unusual condition that occurs rarely as a complication following radiotherapy. Because of the difficulties in the diagnosis of this disease and the need for raising awareness of such as a complication of therapeutic intervention we present a case report and review of the literature with discussion to highlight this disease which can confound the management of breast cancer. Key wordsRadiation, Bullous pemphigoid, Breast cancer, Necrosis, Skin Case presentationA 73-year-old fair-skinned Caucasian female presented for a routine screening mammogram in July of 2012 which demonstrated a suspicious 1.0 cm spiculated solid density in the central region of the left breast. The Breast Imaging Reporting and Data System (BI-RADS) category was assessed as 4. Immediately following the mammogram, the patient underwent a core needle biopsy under stereotactic guidance which revealed a moderately differentiated estrogen and progesterone positive invasive ductal carcinoma. Her 2 neu was not overexpressed and the Ki 67 ratio was 22%. The patient underwent a left sided needle localized lumpectomy and sentinel node biopsy. The final pathology demonstrated a 0.8 cm lesion downgraded to low grade differentiation with negative resection margins. In addition, a small component of ductal carcinoma in-situ was identified in the specimen. No comedonecrosis was identified. The final margins of resection were clear with greater than 0.2 cm circumferentially uninvolved. None of the three sentinel lymph nodes was positive for malignancy. A metastatic work up including a comprehensive metabolic panel, a chest x-ray and routine hematologic indices was within normal limits. Her physical exam demonstrated no abnormalities. The patient had a past medical history significant for essential hypertension, fibrocystic breast change, gastro-esophageal reflux, osteoporosis and benign ovarian cysts. She had no appreciable family history of cancer and used hydrochlorothiazide, esomeprazole, and amlodipine. She was allergic to penicillin, sulfa compounds and codeine. She received 4256 cGy at 266 cGy per fraction to the right breast, completing such in October of the same year. During radiotherapy, the patient developed grade I erythema

show abstract

Incidence and Mortality of Bullous Pemphigoid in France

Cited by 302 publications

References 38 publications

Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid

Our clinical experience with the use of omalizumab in the treatment of bullous pemphigoid

Clinical features and diagnosis of epidermolysis bullosa acquisita

Bullous pemphigoid appearing as superficial tissue necrosis after irradiation of the breast: Case history and definitive review of the literature

Contact Info

Product

Resources

About